Status:
COMPLETED
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
Lead Sponsor:
Abbott
Conditions:
Crohn's Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are int...
Eligibility Criteria
Inclusion
- Patient diagnosed with moderate to severe Crohn's Disease.
- Failed prior infliximab therapy.
- Patient is judged to be in generally good health as determined by the principal investigator.
Exclusion
- Previous treatment with adalimumab.
- Patient considered by the investigator, for any reason, to be an unsuitable candidate
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00338650
Start Date
June 1 2006
End Date
May 1 2007
Last Update
November 29 2007
Active Locations (97)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35209
2
Jonesboro, Arkansas, United States, 72401
3
Little Rock, Arkansas, United States, 72205
4
Roseville, California, United States, 95661